GlobeNewswire Inc | Nov 11, 2020 08:30AM EST

November 11, 2020

WARREN, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 6th Annual Israel Conference.

Presentation DetailsDate: Thursday, November 12, 2020Time: 3:30 PM Eastern Time

A live audio webcast and replay of the presentations will be available in the Investors section on the Companys website at www.bellerophon.com.

About BellerophonBellerophon Therapeuticsis a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. For more information, please visitwww.bellerophon.com.

ContactsAt W2O Group: At LifeSci Advisors:Julie Normart Brian Ritchie(559) 974-3245 (212) 915-2578jnormart@w2ogroup.com britchie@lifesciadvisors.com